• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    'North Carolina Senate Approves Medical Marijuana Regulatory Appointment As House Leader Says 'Heavy-Handed' Tactics Not Helping Legalization's Fate' - Marijuana Moment

    7/3/23 10:43:57 AM ET
    $ACB
    $AKAN
    $CGC
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email

    https://www.marijuanamoment.net/north-carolina-senate-approves-medical-marijuana-regulatory-appointment-as-house-leader-says-heavy-handed-tactics-not-helping-legalizations-fate/

    A Republican North Carolina senator is making it clear that he intends to see his medical marijuana legalization bill pass this session despite some obstinance among GOP leadership in the House—and he’s even gone so far as to include medical cannabis regulatory appointments for the yet-to-be-enacted program in a new measure that passed the Senate last week.

    But Sen. Bill Rabon’s (R) recent acts of defiance—including attaching an amendment to an unrelated House bill that makes its effective date contingent on his medical marijuana legislation becoming law—has ruffled some feathers in the opposite chamber.

    “Any tactics that are perceived as heavy-handed, trying to force it, tend to have the opposite effect,” House Speaker Tim Moore (R) told WNCN-TV.

    “I’ve made it very clear if this bill were to come to the floor, I would support the medicinal use of cannabis. I think it has the right safeguards and protections, so I’m fine with it,” he said. “But, I’m not twisting my members’ arms to vote for it.”

    Another GOP lawmaker who previously supported the reform now says he’s a firm “no” because of the Senate’s stunt, which he described as “pompous” and “self-centered.”

    Rabon doesn’t seem especially concerned, however. While Moore says that he will not bring the cannabis legislation to the floor without majority support from the House GOP caucus, Rabon says that he hopes “some folks will kind of look up and pay attention now” after the Senate passed the other chamber’s unrelated nursing regulations bill with his medical marijuana amendment attached.

    “We have work to be done. We don’t need to stonewall,” he said. “They’re both healthcare bills, and I think they both should be passed this session.”

    Rabon didn’t rule out taking the same action on other House bills to force consideration of the cannabis measure, which passed the Senate as a standalone back in March and received an initial hearing in the House Health Committee last month.

    Still, the amendment tactic hasn’t played well with everyone. Rep. Mike Clampitt (R) told The News & Observer that he was “appalled” by the maneuver.

    “It’s been very divisive in the House, and has been a very contentious topic,” Clampitt said of the overall medical marijuana bill. “And then for the Senate to minimize all of that, and to make a joke out of it, it’s very embarrassing to me for our General Assembly.”

    “They want to play games, I think that’s very unfortunate for the citizens of North Carolina,” he said. “It doesn’t do anyone any good.”

    Rabon’s bill would allow patients with qualifying conditions such as cancer, epilepsy, post-traumatic stress disorder (PTSD) and multiple sclerosis to possess and purchase cannabis from licensed dispensaries.

    It would also establish a Compassionate Use Advisory Board and Medical Cannabis Production Commission to oversee the rollout of the program. And to that end, while the fate of the main bill remains in flux, the Senate passed a separate appointments measure this week that names a member to the Medical Cannabis Production Commission, effective upon enactment of the legalization legislation.

    The House speaker previously said that he felt the chances of passage for the medical cannabis bill were “better” than ever before, despite his latest remarks casting doubt on the prospects of bringing it to the floor this year.

    Moore had said that the dynamics around marijuana reform have changed, with “a lot of new members.” He said that more than 50 percent of his chamber now supports medical cannabis and he would “not be surprised at all if that bill moved.”

    At last month’s House committee hearing, Rabon shared candid personal details about his own experience surviving cancer and using cannabis for treatment. He said that his doctor advised him to use marijuana before he went through serious chemotherapy, and he visited his local law enforcement to tell them that he intended to break the law to use the plant for therapy. Packages of marijuana then regularly showed up in the mail.

    Here are the key provisions of the medical cannabis legislation, SB 3:

    Patients would be allowed to access cannabis if they have a “debilitating medical condition” such as cancer, epilepsy, HIV/AIDS, Parkinson’s disease, multiple sclerosis and post-traumatic stress disorder.

    Smoking and vaping would also be allowed, but doctors would need to prescribe a specific method of delivery and dosages for patients under the revised legislation. And they would need to reevaluate patients’ eligibility for the program at least once a year.

    The bill provides for up to 10 medical marijuana suppliers who control the cultivation and sale of cannabis. Each supplier can operate up to eight dispensaries. That’s double the dispensary cap laid out in the earlier version.

    Under the bill, a Compassionate Use Advisory Board would be established, and it could add new qualifying medical conditions.

    Separately, a Medical Cannabis Production Commission would be created to ensure that there’s an adequate supply of cannabis for patients, oversee licensing and generate enough revenue to regulate the program.

    The measure would further create a North Carolina Cannabis Research Program to “undertake objective, scientific research regarding the administration of cannabis or cannabis-infused products as part of medical treatment.”

    There don’t appear to be specific equity provisions that many advocates push for as part of legalization legislation.

    A findings section in the bill states that it’s the intent of the legislature “prioritize the protection of public health and safety in the creation of a system for the cultivation, processing, and selling of medical cannabis.”

    Further, “the General Assembly that the regulatory system created by this Article be nimble and able to respond quickly to changes in the rapidly-evolving cannabis industry.”

    A poll released in February found that North Carolinians are also ready for the reform, with about three in four voters saying they back medical cannabis legalization.

    For his part, Gov. Roy Cooper (D) said in December that he thinks a medical marijuana legalization bill “has an opportunity to pass” this session, and he also reiterated his support for broader decriminalization of cannabis possession, noting racial disparities in enforcement.

    Cooper’s public support for decriminalization is a relatively recent development. He first openly backed the policy change in October, saying that it’s time to “end the stigma,” while separately announcing steps he’s taken to explore his options for independently granting relief to people with existing convictions.

    Following President Joe Biden’s mass pardon announcement in October, which also involved a call to action for governors to provide state-level relief, Cooper said that he’s directed state attorneys to review pardon authority for marijuana offenses.

    The governor separately convened a North Carolina Task Force for Racial Equity in Criminal Justice that previously recommended decriminalizing marijuana. The report from the panel, which is chaired by state Attorney General Josh Stein (D), also included a recommendation for the state to initiate a study on whether to more broadly legalize cannabis sales.

    Under current law, possessing more than half an ounce up to 1.5 ounces of cannabis is a class 1 misdemeanor, subject to up to 45 days imprisonment and a $200 fine. In 2019, there were 3,422 such charges and 1,909 convictions, with 70 percent of those convicted being nonwhite.

    Meanwhile, a North Carolina House committee approved a bill last month to create a $5 million grant program to support research into the therapeutic potential of psilocybin and MDMA and to create a Breakthrough Therapies Research Advisory Board to oversee the effort.

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $AKAN
    $CGC
    $CRON

    CompanyDatePrice TargetRatingAnalyst
    Tilray Brands Inc.
    $TLRY
    4/3/2026$10.00Neutral → Buy
    Roth Capital
    Tilray Brands Inc.
    $TLRY
    4/2/2026$10.00Neutral → Buy
    Roth Capital
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    Aurora Cannabis Inc.
    $ACB
    1/27/2026Buy
    Canaccord Genuity
    Cronos Group Inc.
    $CRON
    1/27/2026Buy
    Canaccord Genuity
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    SNDL Inc.
    $SNDL
    9/3/2025$5.00Buy
    Alliance Global Partners
    More analyst ratings

    $ACB
    $AKAN
    $CGC
    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Prins Richard K

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:50 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mukunda Ram

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:29 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moran James P

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:01 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AKAN
    $CGC
    $CRON
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    4/16/26 4:18:36 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    4/15/26 4:35:07 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Tilray Brands Inc.

    424B5 - Tilray Brands, Inc. (0001731348) (Filer)

    4/15/26 9:13:28 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $AKAN
    $CGC
    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/3/26 10:44:58 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray upgraded by Roth Capital with a new price target

    Roth Capital upgraded Tilray from Neutral to Buy and set a new price target of $10.00

    4/2/26 7:55:13 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $AKAN
    $CGC
    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL to Report First Quarter 2026 Financial Results on April 29, 2026

    EDMONTON, Alberta, April 15, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2026 financial results for the period ended March 31, 2026, before markets open on Wednesday, April 29, 2026. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on April 29, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/9eyekwcv  ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis com

    4/15/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership

    NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced a series of strategic initiatives marking its next phase of global growth, expanding its leadership across healthcare, cannabis and beverage while strengthening its ability to expand internationally and capture emerging market opportunities. Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated: "Tilray Brands is setting the pace for global innovation across healthcare, cannabi

    4/15/26 7:40:44 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets

    NASDAQ | TSX: ACBEDMONTON, AB, April 15, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "Transaction"). "The acquisition of Safari Flower Company marks an impor

    4/15/26 7:05:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $AKAN
    $CGC
    $CRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Aiello Stephen bought $221,334 worth of shares (133,334 units at $1.66), increasing direct ownership by 25% to 668,311 units (SEC Form 4)

    4 - GrowGeneration Corp. (0001604868) (Issuer)

    9/23/25 4:00:54 PM ET
    $GRWG
    RETAIL: Building Materials
    Consumer Discretionary

    $ACB
    $AKAN
    $CGC
    $CRON
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces Leadership Transition for Cannabis Segment

    EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") announced today that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL's current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours. ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquo

    3/30/26 5:00:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab

    3/16/26 7:41:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    $AKAN
    $CGC
    $CRON
    Financials

    Live finance-specific insights

    View All

    SNDL to Report First Quarter 2026 Financial Results on April 29, 2026

    EDMONTON, Alberta, April 15, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its first quarter 2026 financial results for the period ended March 31, 2026, before markets open on Wednesday, April 29, 2026. Following the release of its first quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on April 29, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/9eyekwcv  ABOUT SNDL INC. SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis com

    4/15/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026

    NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the third fiscal quarter which ended February 28, 2026, before the financial markets open on Wednesday, April 1, 2026. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Ti

    3/25/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    GrowGeneration Reports Fourth Quarter and Full Year 2025 Financial Results

    Full Year Net Sales of $161.7 million including Proprietary Brand Sales of $44.0 million Full Year Proprietary Brand Penetration Increased to 32.8% up from 24.2% in the prior year Full Year GAAP Net Loss Improved by $25.5 million; Adjusted EBITDA Improved by $8.5 million $46.1 million of Cash and Marketable Securities and no debt Board Authorizes $10 Million Share Repurchase Program 2026 Outlook: Revenue of $162 million to $168 million and Breakeven Adjusted EBITDA(1) DENVER, March 19, 2026 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ:GRWG), ("GrowGeneration," "GrowGen" or the "Company"), one of the nation's largest suppliers of specialty products for controlled envir

    3/19/26 4:05:00 PM ET
    $GRWG
    RETAIL: Building Materials
    Consumer Discretionary

    $ACB
    $AKAN
    $CGC
    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Leafly Holdings Inc.

    SC 13G/A - Leafly Holdings, Inc. /DE (0001785592) (Subject)

    11/14/24 5:35:46 PM ET
    $LFLY
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by GrowGeneration Corp.

    SC 13G/A - GrowGeneration Corp. (0001604868) (Subject)

    11/12/24 3:53:28 PM ET
    $GRWG
    RETAIL: Building Materials
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Leafly Holdings Inc.

    SC 13G/A - Leafly Holdings, Inc. /DE (0001785592) (Subject)

    11/12/24 1:25:25 PM ET
    $LFLY
    Computer Software: Prepackaged Software
    Technology